VYGR NASDAQ
Voyager Therapeutics, Inc.
1W: -8.6%
1M: -30.8%
3M: -32.3%
YTD: -39.2%
1Y: -47.6%
3Y: -68.3%
5Y: -16.7%
$2.45
-0.23 (-8.41%)
Weekly Expected Move ±7.2%
$2
$2
$2
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships9
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2021-10-06
Earliest Filing
2024-09-05
Latest Filing
partner: 7
customer: 2
Counterparties (Filed by VYGR)
9 relationshipsCompanies named in VYGR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Novartis Pharma AG | NVSEF | partner | Amendment to Option and License Agreement granting exclusive license for a capsid target | 2024-09-05 | View |
| Citigroup Global Markets Inc. | — | partner | Underwriter representative for the public stock offering | 2024-01-08 | View |
| Novartis Pharma AG | NVSEF | customer | Counterparty in a private stock purchase and license collaboration agreement | 2024-01-08 | View |
| Novartis Pharma AG | NVSEF | partner | Entered into a License and Collaboration Agreement for AAV capsids and a Stock Purchase Agreement for common stock. | 2024-01-02 | View |
| Neurocrine Biosciences, Inc. | NBIX | partner | Existing collaboration partner mentioned in the context of reimbursement for development costs. | 2024-01-02 | View |
| Neurocrine Biosciences, Inc. | NBIX | partner | Entered into a Collaboration and License Agreement and Stock Purchase Agreement for gene therapy development and commerc | 2023-01-09 | View |
| BRE-BMR Pilgrim & Sidney LLC | — | partner | Landlord in lease termination agreement | 2022-06-23 | View |
| BioNTech US Inc. | BNTX | customer | Sublessee in sublease termination agreement | 2022-06-23 | View |
| Pfizer Inc. | PFE | partner | Voyager Therapeutics granted Pfizer options to receive an exclusive license to novel capsids for developing and commerci | 2021-10-06 | View |
Mentioned As Counterparty
1 mentionsOther companies that named VYGR in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-13 | Other Events | View | |
| 2026-06-10 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-06-01 | Other Events | View | |
| 2026-04-21 | Officer/Director Change | View | |
| 2026-03-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-12 | Departure/Election of Directors; Appointment of Officers; Other Events | View | |
| 2026-01-08 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-02 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-05 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-11 | Other Events | View | |
| 2024-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-05 | Entry into Material Definitive Agreement | Agreement | View |
| 2024-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-06 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-04-02 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR